Setting the Record Straight on FDA Approvals in Oncology-Reply.

Setting the Record Straight on FDA Approvals in Oncology To the Editor The Research Letter, “Quality of Life, Overall Survival and Costs of Cancer Drugs Approved Based on Surrogate Endpoints,”1 by Rupp and Zuckerman and the accompanying Editor’s Note “Improving the Accelerated Pathway to Cancer Drug Approvals”2 by Bauer and Redberg, both published in a… CONTINUE READING